Robert Lutz was named Chief Financial and Operating Officer of Savara Inc, effective July 15, 2026. As of November 6, 2026, Savara Inc has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on June 8, 2026, naming 1 appointment (Form 8-K, June 8, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Savara Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Savara Inc reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-06-08. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Savara Inc files it.
Also on the record for Savara Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| February 17, 2026 | Stake report, Schedule 13G/A, by TCG Crossover GP I, LLC | 6.1% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Venrock Healthcare Capital Partners III, L.P. | 9.9% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by Frazier Life Sciences Public Fund, L.P. | 4.1% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by Nantahala Capital Management, LLC | 3.61% of the class | 5%+ stakes | Source |
| February 5, 2026 | Stake report, Schedule 13G/A, by Dapice Joshua J. | 6.9% of the class | 5%+ stakes | Source |
| January 21, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 5.4% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13D/A, by Growth Equity Opportunities 17, LLC | 12% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G, by Nantahala Capital Management, LLC | 5.08% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Venrock Healthcare Capital Partners III, L.P. | 7.3% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by Vestal Point Capital, LP | 2.3% of the class | 5%+ stakes | Source |
| November 5, 2025 | Stake report, Schedule 13G, by Deerfield Mgmt, L.P. | 6.74% of the class | 5%+ stakes | Source |
| October 17, 2025 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 4.8% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Savara Inc now and the warning signs.
Free to see. No signup.
Keep reading
More on Savara Inc and the records around it.
Savara Inc elsewhere on the record
- 5%+ stake filings Feb 2026
- Who owns it
Companies that share a holder
- TCG Crossover GP I, LLC also filed stake reports on 6 other companies: Abivax SA (Aug 2026), Entrada Therapeutics, Inc. (Aug 2026), Vistagen Therapeutics, Inc. (Aug 2026)
- Deerfield Mgmt, L.P. also filed stake reports on 19 other companies: Climb Bio, Inc. (Oct 2026), Cogent Biosciences, Inc. (Aug 2026), Enhabit, Inc. (Aug 2026)
- Farallon Capital Partners, L.P. also filed stake reports on 19 other companies: BridgeBio Pharma, Inc. (May 2026), InflaRx N.V. (May 2026), Beta Bionics, Inc. (May 2026)
Watch Savara Inc
Get an email when Savara Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Savara Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Savara Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Savara Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 14 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-06-08 | In | Chief Financial and Operating Officer | 2026-07-15 | 8-K, 2026-06-08 |
Who leads Savara Inc, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial and Operating Officer: Robert Lutz, appointed, effective 2026-07-15 (filed 2026-06-08).
New leaders reset buying decisions — get the Full Report on Savara Inc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial and Operating Officer at Savara Inc, with the record behind each one.
Find candidates like Chief Financial and Operating Officer at Savara IncEvery change, in the filing's words
Appointed: Robert Lutz, Chief Financial and Operating Officer, effective 2026-07-15
The foregoing description of the 2024 Plan Amendment is qualified in its entirety by reference to the full text of the 2024 Plan, as amended by the 2024 Plan Amendment, which is attached to the Proxy Statement as Appendix B. Executive Transition On June 5, 2026, the Board appointed Robert Lutz to become the Chief Financial and Operating Officer of Savara effective July 15, 2026 (the "Effective Date").
- Amendment of 2024 Omnibus Incentive Plan On June 4, 2026, the stockholders of Savara Inc. ("Savara") approved an amendment to the Savara Inc. 2024 Omnibus Incentive Plan (the "2024 Plan"), to increase the number of shares of common stock authorized for issuance thereunder by 18,900,000 shares (the "2024 Plan Amendment").
- The 2024 Plan Amendment was previously approved by Savara's Board of Directors (the "Board"), subject to stockholder approval.
- The 2024 Plan Amendment is described in detail under "Proposal 3 - Approval of an Amendment to our 2024 Omnibus Incentive Plan" of the Savara Definitive Proxy Statement on Schedule 14A, which was filed with the U.S. Securities and Exchange Commission on April 24, 2026 (the "Proxy Statement").
- Mr. Lutz's appointment follows the decision of David Lowrance to resign from his role as Savara's Chief Financial and Administrative Officer, effective as of the Effective Date, due to health reasons.
- Mr. Lowrance will receive severance in accordance with the terms of Section 6(a) of his employment agreement and 12 months' acceleration of the vesting of his unvested equity awards as of the Effective Date, provided that he signs and does not revoke a customary release in favor of Savara.
Tools for this story
Each opens in a new tab, filled in for Savara Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.